Alaunos Therapeutics (TCRT) Capital Leases (2019 - 2023)

Alaunos Therapeutics has reported Capital Leases for 5 years, with the latest figure at $864000.0 in Q3 2023.

• For the quarter ending Q3 2023, Capital Leases fell 62.98% year-over-year to $864000.0; the trailing twelve-month figure through Sep 2023 stood at $864000.0 (down 62.98% YoY), and the FY2022 full-year result was $2.2 million, down 51.57% from the prior year.
• Capital Leases for Q3 2023 stood at $864000.0, down from $1.2 million in the prior quarter.
• The five-year high for Capital Leases was $4.5 million in Q4 2021, with the low at $647000.0 in Q3 2019.
• Historically, Capital Leases has averaged $2.0 million across 5 years, with a median of $1.6 million in 2019.
• Annual changes were most pronounced in 2020 — Capital Leases surged 155.8% — and 2023, when it plunged 62.98%.
• Alaunos Therapeutics' Capital Leases stood at $1.6 million in 2019, then surged by 153.17% to $4.0 million in 2020, then rose by 13.09% to $4.5 million in 2021, then plunged by 51.57% to $2.2 million in 2022, then plunged by 60.51% to $864000.0 in 2023.
• The last three Capital Leases figures came in at $864000.0 (Q3 2023), $1.2 million (Q2 2023), and $2.0 million (Q1 2023), per Business Quant data.